Drugmakers Sanofi, Eli Lilly, Novo Nordisk and AstraZeneca must face a lawsuit from two health centers accusing them of ...

The Second Circuit revived an antitrust case Wednesday against AstraZeneca Plc and three other pharmaceutical firms, saying ...

Pfizer (PFE), and Sanofi (SNY) drew increased attention on Tuesday as traders reacted to the U.S. government’s move to halt ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

The Department of Health and Human Services is terminating around $500 million in BARDA contracts associated with mRNA ...

A panel of federal appeals judge ruled that four major drug makers acted similarly enough in substance and timing by restricting pharmaceutical subsidies and raising prices of certain popular diabetes ...

The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

The Department of Health and Human Services (HHS) has announced a plan to end mRNA vaccine work funded by the Biomedical ...

76% of patients in the Dupixent trial reached ≥75% improvement in eczema severity at 24 weeks. Sanofi has tripled Beyfortus production and doubled manufacturing sites since its 2023 launch. PPI ...

U.K.-based drug giant AstraZeneca will make what it calls its single-largest manufacturing investment in the world with a new facility in Virginia.